WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline

---
WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline
Vote:
0 0
Previous Beko Secures #1 Spot for Household Durables Industry in the Corporate Knights Global 100
Next China's Best-Selling Model Geely EX2 Launched in Indonesia, Accelerating Global Expansion via Local Manufacturing

Related News

HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline

WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List

WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers

WuXi Biologics to Increase Manufacturing Capacity in Germany

WuXi Biologics Again Passed GMP Inspection by Japan PMDA

WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager

menu
menu